News GlycoNex Incorporation

Stocks

4168

TW0004168000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 2026-10-30			5-day change	1st Jan Change
21.30 ^TWD	-0.70%		-0.70%	-17.28%

08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-02	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI

All News

Mentions Relevance

08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-02	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
06-10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
03-23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
03-13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
11-24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
11-14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
25-10-29	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
25-08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-12	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI
25-05-27	GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules	CI
25-05-12	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-14	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-10	Recent Ustekinumab And Denosumab Biosimilars Deals	AQ
25-01-06	Glyconex, Inc. Announces Licensing Agreement for Spd8 Biosimilar	CI
24-12-17	GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar	CI
24-11-12	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-16	Glyconex Incorporation Completes the First Phase Trial of Biosimilar Drug Spd8 and Will Start the Third Phase Clinical Trial	CI
24-08-11	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-05-28	Glyconex and Precisemab Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy	CI
24-05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI